Biomarker Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers

Epigenetics Clinical Trial

Official title:

The NAD+ Baseline Study: a Biomarker-based Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04220658
• Other study ID #: Baseline Study
• Status: Suspended
• Start date: December 19, 2019
• Est. completion date: December 3, 2023

Study information

• Verified date: February 2023
• Source: Elysium Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a single center, prospective study to evaluate correlations between epigenetic aging (as measured via DNA methylation) and NAD+ levels in healthy volunteers.

Description:

This biomarker study consists of a single outpatient visit to the research unit. At this visit, eligibility will be assessed and biomarker samples (blood, saliva and urine) will be collected from subjects meeting eligibility criteria. Consenting subjects with clinically significant screening lab values may be excluded from the study after biomarker sample collection (i.e., clinical lab test results will become available after the biomarker sample collection). The prescribing of drugs to humans will not be part of this protocol.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 170
• Est. completion date: December 3, 2023
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Males or females between 25 - 80 (inclusive) years of age

2. Able and willing to provide written consent, follow instructions to complete study questionnaire(s) and assessments

3. Peripheral venous access sufficient for blood draw

Exclusion Criteria:

1. History of any significant chronic disease including renal, liver, endocrine, inflammatory, cardiovascular, gastro-intestinal, neurological, psychiatric, neoplastic, or metabolic disease, unless well controlled (defined as stable medication regimen) for at least 90 days prior to screening. Clinical significance of active disease will be assessed by the Qualified Investigator to determine eligibility.

2. Clinically significant, unstable or untreated medical disorders including recent myocardial ischemia or infarction, unstable angina, uncontrolled hypertension, AIDS, malignancy, epilepsy, and recent cerebrovascular disease that required a change in management or hospitalization within the last 90 days.

3. Subjects with or who have recently experienced a traumatic injury, infections or undergone major surgery at the discretion of the Qualified Investigator

4. Donation or receipt of blood products within 90 days.

5. Clinically significant vital sign or physical examination abnormality at the discretion of the Qualified Investigator.

6. Subjects with history of pellagra or niacin deficiency

7. Alcohol use >2 standard alcoholic drinks per day within the past month

8. History of alcoholism or drug abuse within 1 year prior to screening

9. Use of medical marijuana or products containing cannabinoids in the 14 days prior to screening.

10. Use of lipid lowering agents (including fish oil) unless the dose has been stable for greater than 90 days prior to screening.

11. Use of natural health products containing nicotinamide riboside or niacin exceeding the RDA (16mg/day for males and 14mg/day for females) within 14 days prior to Screening. Potential participants will be asked to bring all supplements for evaluation at time of screening.

12. History of or current diagnosis of any cancer (except for successfully treated basal or squamous cell carcinoma of the skin) diagnosed less than 5 years prior to screening. Volunteers with cancer in full remission and more than 5 years after diagnosis are acceptable.

13. Has participated in any clinical trial with an investigational medicinal product within the past two months prior to the first dose in the current study

14. Clinically significant abnormal laboratory results at screening

15. Any other condition which in the Investigator's opinion may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant

16. Consumption of non-water beverage or food within approximately 8 hours of sample collection

Related Conditions & MeSH terms

• Epigenetics

Intervention

Other:
• Biomarker study
Biomarkers of aging including NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation

Locations

Country	Name	City	State
United States	Duke Early Phase Clinical Research	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Elysium Health	Duke Clinical Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Age related markers in blood and urine	Correlations between biological age, calculated from DNA isolated from blood and saliva, and the following age-related markers observed in blood and urine: Cellular senescence, proliferation and inflammation: CD3+ and p16INK4a+ T lymphocytes, TNF-a R1, IL-6, IL-8, IL-10, C-reactive protein, eotaxin, activin A, myostatin.; NAD-related biomarkers: CD38; Cellular health and bioenergetics: mitochondrial DNA and nuclear DNA	At baseline
Primary	Correlation between biological age, calculated using DNA isolated from blood, and circulating NAD+ levels		At baseline
Secondary	Correlations between biological age, calculated using DNA isolated from saliva, and circulating NAD+ levels		At baseline
Secondary	Correlations between biological age, calculated using DNA isolated from blood and saliva, and Omega-3 levels in blood		At baseline